Tisotumab Vedotin (HuMax®-TF-ADC) Safety Study in Patients With Solid Tumors

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

33

Participants

Timeline

Start Date

November 30, 2015

Primary Completion Date

December 13, 2017

Study Completion Date

December 13, 2017

Conditions
Ovary CancerCervix CancerEndometrium CancerBladder CancerProstate Cancer (CRPC)Esophagus CancerLung Cancer (NSCLC)
Interventions
DRUG

Tisotumab vedotin (HuMax-TF-ADC)

Trial Locations (16)

1000

Institut Jules Bordet, Brussels

1083

Semmelweis Egyetem Onkológiai Központ, Budapest

1200

Cliniques Universitaires Saint-Luc, Brussels

3000

Universitaire Ziekenhuizen Leuven, Leuven

4000

CHU de Liège, Liège

4032

Debreceni Egyetem Klinikai Központ, Debrecen

5000

CHU UCL Namur - Sainte Elisabeth, Namur

5530

CHU UCL Namur - site Godinne, Yvoir

6000

Grand Hôpital de Charleroi, Charleroi

9023

Petz Aladár Megyei Oktató Kórház, Győr

77030

MD Anderson Cancer Center, Houston

DK-2100

Rigshospitalet, Copenhagen University Hospital, Copenhagen

NW1 2PG

University College London Hospitals NHS Foundation Trust, London

W1G 6AD

Sarah Cannon Cancer Center, London

M20 4BX

The Christie NHS Foundation Trust, Manchester

SM2 5PT

The Royal Marsden NHS Foundation Trust, Sutton

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Genmab

INDUSTRY

lead

Seagen Inc.

INDUSTRY

NCT02552121 - Tisotumab Vedotin (HuMax®-TF-ADC) Safety Study in Patients With Solid Tumors | Biotech Hunter | Biotech Hunter